Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;119(1):213-222.
doi: 10.1002/jcb.26136. Epub 2017 Jul 4.

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

Afsane Bahrami  1   2 , Majid Khazaei  3 , Soodabeh Shahidsales  4 , Seyed Mahdi Hassanian  5   6 , Malihe Hasanzadeh  7 , Mina Maftouh  5 , Gordon A Ferns  8 , Amir Avan  5
Affiliations
Review

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

Afsane Bahrami et al. J Cell Biochem. 2018 Jan.

Abstract

Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR pathway is among the most frequently dysregulated pathways in patients with BC. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential therapeutic target in the treatment of BC. The aim of current review is to provide an overview of the potential utility of PI3K/Akt/mTOR inhibitors in patients with BC, with particular emphasis on recent preclinical and clinical studies. J. Cell. Biochem. 119: 213-222, 2018. © 2017 Wiley Periodicals, Inc.

Keywords: BREAST CANCER; EVEROLIMUS; PI3K/Akt/mTOR INHIBITORS.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources